Patient Recruitment · 2026
Three Targeted Channels vs Five Broad Channels
There’s a persistent instinct in recruitment planning: more channels means more patients. It doesn’t — channel count and channel quality are different things, and treating them as the same is one of the more expensive planning mistakes in recruitment strategy.
Panacea Patient Recruitment · Patient recruitment specialists for clinical trials · Last updated: 29 August 2026
Patient Recruitment · 2026
Three Targeted vs
Five Broad Channels
More channels isn’t a wider funnel
Three targeted channels vs five broad channels is a comparison recruitment planning gets backwards constantly — the wider-looking five-channel strategy is usually the weaker one, because channel count and channel relevance are not the same thing.
Key Takeaways
- Adding channels doesn’t just fail to help. Broad, low-relevance channels can actively drag down the average relevance of a source mix that was otherwise working — it’s the average relevance of the strategy that determines whether the funnel works, not the number of taps open.
- Broad mass-market channels (TV, radio, newspaper) reach a lot of people and almost nobody specifically relevant to a given study — they were built to reach a general population, not to find a specific eligibility profile.
- In a real clinical trial recruitment case study, a grassroots, targeted approach recruited 638 participants in 4 months with 91% of screening calls meeting eligibility, while the original plan had allocated 80% of the budget to mass media — the team cut that share dramatically and still saved 30% of the total recruitment budget (Murphy & Merenstein, 2011).
- General marketing effectiveness research analysing over 250 case studies found three advertising channels to be the most effective number for driving hard business results — the same “fewer, better-matched” pattern shows up directly in recruitment source-mix scoring.
- A tightly targeted four-channel mix for a common-condition study can score as well as a three-channel rare-disease mix, because every channel in it is either clinically-connected or intent-led — the same logic covered in patient source mix for rare disease vs common conditions.
- Digital and social acquisition scores respectably even as a single channel, because continuous, targetable fresh-enquiry generation is a genuinely strong source in its own right.
- An existing patient database is a static, decaying asset: contact lists degrade by roughly 23% a year on average, so the “safe default” channel can quietly be doing less work than an active digital one.
Three targeted channels vs five broad channels: why does the smaller mix usually win?
There’s a persistent instinct in patient recruitment planning: more channels means more patients. Add a radio spot, a newspaper ad, a TV slot on top of your digital and clinical sourcing, and surely the funnel only gets wider. It doesn’t. Channel count and channel quality are different things, and treating them as the same is one of the more common — and more expensive — planning mistakes, closely related to the topline-number blind spot covered in the hidden cost of a good-enough recruitment percentage.
What is the channel-count trap, and why do broad channels fall into it?
Broad mass-market channels reach a lot of people. They also reach almost nobody who’s specifically relevant to a given study, which is why they carry limited targeting precision by design. Compare that to a patient advocacy organisation, trusted by its own members and a genuinely strong channel for a rare-disease study, or search advertising, where the audience arrives already actively looking for something related to their condition. These aren’t just “another source” — they’re structurally different in how likely they are to produce a relevant, engaged patient.
Adding five channels where three would do doesn’t just fail to help. If the extra two are broad, low-relevance channels, they can actively drag down the quality of the source mix as a whole — because the average relevance of a sourcing strategy is what determines whether the funnel is actually working, not the number of taps that have been opened.
What do four realistic targeted-vs-broad channel mixes actually show?
The pattern holds across every realistic combination. Three targeted channels — Key Opinion Leaders, patient advocacy organisations, and an investigator-site database — score strongly, because all three carry real relevance to that population. Five mass-market channels score meaningfully lower despite looking like the broader strategy on paper. A tightly targeted four-channel mix for a common-condition study — site database, GP referral, search advertising, and digital/social — scores just as well as the three-channel rare-disease mix. And digital/social acquisition alone scores respectably even as a single channel.
3 targeted channels
4 targeted channels
Digital/social alone
5 broad channels
Row 4 has more channels than rows 1-2 and scores lowest — count and quality aren’t the same thing. Illustrative relevance-weighted comparison, not an external published dataset.
| Signal | Targeted, relevance-first mix | Broad, reach-first mix |
|---|---|---|
| Typical composition | Clinical referral, patient advocacy, investigator-site database | Television, radio, newspaper, plus website/social enquiries |
| Population relevance | Every channel structurally connected to the eligible population | Built for a general audience, not this study's population |
| Call/enquiry precision | 91% of screening calls met eligibility in a targeted-recruitment case study | The same study's mass-media plan risked flooding the line with low-eligibility callers |
| Budget pattern in practice | Absorbed the reallocated share of the recruitment budget | Cut back sharply from a planned 80% share, with total spend still down 30% overall |
| Best fit | A well-matched three- or four-channel mix, rare or common condition | Rarely outperforms a smaller targeted mix, even though it looks broader on a slide |
Why does mass media reach so many people and convert so few?
The clearest documented illustration comes from a real pediatric clinical trial recruitment case study. The original plan allocated 80% of the budget to mass media. The team instead ran a grassroots, community-first campaign and recruited 638 participants in just 4 months, retaining over 90% through the 90-day trial. Of 872 calls to the screening line, 741 were screened and 681 — 91% — met eligibility. Eighty- four percent of participants learned about the study through daycare, school, or other community and word-of-mouth sources. The team cut mass media’s budget share dramatically and still saved 30% of the total recruitment budget.
The same pattern shows up in rare-disease recruitment specifically: a registry/email contact channel converted 18.22% of referrals to consented leads in one study, versus 6.8% for organic Facebook and just 1% for paid Facebook ads — precision beat reach by more than an order of magnitude, covered in more depth in patient source mix for rare disease vs common conditions. And it isn’t unique to clinical recruitment: an analysis of over 250 marketing effectiveness case studies found three channels to be the most effective number for driving hard business results.
Why does digital acquisition deserve a second look?
Digital and social-media sourcing is often treated as a supplementary channel, ranked below an existing patient database on the assumption that a known population is inherently safer. In practice, the opposite tends to be true operationally. An existing database is a static, decaying asset — contact lists degrade by roughly 23% a year on average, generating fewer genuinely new patients as a study progresses. Digital and social acquisition generates fresh enquiries continuously and is usually highly targetable, which makes it a stronger ongoing channel — a readiness factor that matters as much once recruitment opens as how quickly those enquiries get a first response.
What does a targeted channel mix mean for recruitment budget conversations?
If channel count were the thing that mattered, the instinct to “cover all the bases” with a wide media buy would make sense. It doesn’t, because the bases aren’t equal. The more useful question isn’t how many channels are we running — it’s how many of our channels are structurally suited to finding this specific population, the same reframing that underlies setting a study-specific recruitment benchmark. A single well-matched clinical or community channel is doing more recruitment work than three mismatched mass-market ones combined. Knowing this also depends on being able to trace which channel actually produced which outcome — the chain covered in clinical trial recruitment source attribution.
How do you build a source strategy around relevance, not reach?
If you’re planning or reviewing a recruitment source mix, the questions worth asking are the same ones a structured diagnostic would ask.
- Does each channel have a structural reason to reach this population, not just a general population?
- Are we relying on breadth to compensate for a lack of targeted channels, including clinical referral pathways that may already exist but aren't being used fully?
- Is an existing database being treated as a safe default when a more active digital channel might now be doing more work?
- If we dropped our weakest channel, would our overall source quality go up?
That last question is often the most revealing one. If the answer is yes, the channel isn’t adding coverage — it’s diluting it, the same diagnosis a proper under-enrolment review is built to surface rather than assuming the sourcing strategy needs to be bigger.
See how your own source mix scores on relevance, not headcount
A structured recruitment diagnostic shows how your source mix scores on relevance and diversity, not just number of channels — and where a smaller, sharper strategy might outperform a broader one.
Take the Recruitment DiagnosticMethodology & sourcing note
The clinical-trial-specific anchor for this article is Murphy & Merenstein’s 2011 account of the DRINK study’s grassroots recruitment campaign, published in Clinical Medicine Insights: Pediatrics. The registry/email-vs-social-ads figures (Applequist et al., 2023) and the email list-decay figure (ZeroBounce, 2025) are reused from this series’ article on patient source mix for rare disease vs common conditions. The IPA Databank “three channels” finding is general marketing-effectiveness research, not clinical-trial-specific, and is disclosed here as analogous evidence for the same mechanism. The source-mix scoring pattern in the ranked chart above illustrates a relevance-weighted comparison of realistic channel combinations rather than an external published dataset.
Frequently asked questions
Panacea Patient Recruitment
Patient recruitment specialists for clinical trials · panaceapatientrecruitment.com/about-us
Last updated: 29 August 2026